An Open-label Comparison of a New Generic Sevoflurane Formulation with Original Sevoflurane in Patients Scheduled for Elective Surgery under General Anesthesia

Hyo Jin Byon, Byung Moon Choi, Ji Yeon Bang, Eun Kyung Lee, Sang Seok Lee, Gyu Jeong Noh

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Purpose To compare the stability, effectiveness, and safety profiles of a new generic sevoflurane with those of the original sevoflurane formulation in patients undergoing elective surgery. Methods An accelerated 3-month storage test was performed to evaluate the compositional changes in generic sevoflurane stored in glass bottles. In addition, 182 patients were randomly allocated to receive generic (n = 89 [54 men and 35 women]; mean [SD] age, 49.9 [11.6] years) or original (n = 93 [61 men and 32 women]; mean [SD] age, 49.6 [11.1] years) sevoflurane at a gas flow of 3 L/min for approximately 3 hours. The mean minimum alveolar concentration (MAC) during sevoflurane anesthesia was evaluated, and gas samples for measuring compound A were collected from the inspiratory limb of the circuit at preset intervals. Blood samples for measuring serum inorganic fluoride were obtained at preset intervals (pharmacokinetic group: generic/original sevoflurane = 45/46). Renal biomarkers, such as N-acetyl-β-glucosaminidase, α- and π-glutathione-S-transferase, albumin, urine protein and osmolality, serum creatinine and osmolality, creatinine clearance, and blood urea nitrogen, were measured at preset intervals (renal biomarker group: generic/original sevoflurane = 44/47). Adverse reactions were monitored for 72 hours after discontinuation of sevoflurane use. Findings Generic sevoflurane contained in glass bottles was stable for 3 months. The mean MAC was similar for generic and original sevoflurane (median [range], 0.93 [0.67-1.29] vs 0.94 [0.63-1.5] vol%). Adverse event rates were similar (90.3% vs 84.3%), as were the AUClast of inorganic fluoride (333.7 [112.7-1264.7] vs 311.9 [81.5-1266.5] hours·μmol/L) and compound A (51.8 [6.3-204.5] vs 55.3 [10.8-270.6] hours·ppm). Biomarkers associated with renal injury were not significantly different between the 2 formulations. Implications No significant difference was found in the mean MAC between generic and original sevoflurane. ClinicalTrials.gov identifier: NCT01096212.

Original languageEnglish
Pages (from-to)887-901
Number of pages15
JournalClinical Therapeutics
Volume37
Issue number4
DOIs
StatePublished - 1 Apr 2015

Bibliographical note

Funding Information:
This study was supported by Hana Pharmaceutical, Co., Ltd., Seoul, Korea.

Publisher Copyright:
© 2015 Elsevier HS Journals, Inc. All rights reserved.

Keywords

  • compound A
  • effectiveness
  • generic sevoflurane
  • inorganic fluoride

Fingerprint

Dive into the research topics of 'An Open-label Comparison of a New Generic Sevoflurane Formulation with Original Sevoflurane in Patients Scheduled for Elective Surgery under General Anesthesia'. Together they form a unique fingerprint.

Cite this